Lupin Ltd. has introduced a partnered with Amman Pharmaceuticals Industries , a pharmaceutical producer with operations throughout the MENA area and different world markets, for unique marketing and commercialisation of Ranibizumab, a biosimilar of Lucentis, within the Middle East area, together with choose territories of Jordan, Saudi Arabia, UAE, Iraq, Lebanon, and different GCC international locations.
“Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV),” the corporate stated.
“Our aim is to be at the forefront of transforming patient’s lives and building a healthier, brighter future for all. We are excited about the partnership with Amman Pharma to bring Ranibizumab to the MENA region,” stated Nilesh Gupta, Managing Director, Lupin.
Dr. Fadi Alatrash, General Manager of Amman Pharma stated, “This partnership is aligned with our mission to provide high-quality products and access to advanced biosimilars to patients in the region. It also expands our biosimilar portfolio and strengthens our position in the niche Ophthalmology market.”
